INFORMATION

We specialize in organizing high-quality business events, which provide only need-to-know information from leading industries’ experts.

CONTACT INFO

Email: registration@curtiswyss.com

Phone: +420 222 280 104

FOLLOW ME
Protein Degradation Summit
Curtis & Wyss Group is pleased to invite you to the Protein Degradation Summit scheduled for The upcoming B2B event brings together scientists and experts who want to discuss the full and comprehensive range of up and coming protein degrading strategies to achieve efficient degradation of a broad range of disease-causing targets, with the possibility to hear the latest developments and advancements from the leaders of the protein degradation field to maximize the therapeutic window of the protein degradation strategies.

Do not miss this opportunity to join the largest community of protein degradation experts for a deep dive into clinical development progress, lessons learnt and novel strategies to develop safe, selective, and effective PROTACs, molecular glues, and autophagy-mediated degraders for oncology and beyond. We look forward to seeing you at the Protein Degradation Summit scheduled for 28th-29th of October.

HIGHLIGHTS

Mechanisms of PROTAC resistance;

Updates of ongoing clinical trials;

Protein degradation Case Studies to optimize clinical development;

Approaches to penetrating the blood brain barrier;

Plethora of disease indications targeted by PROTACs;

Robust Translation & Clinical Development Considerations;

Understanding the mechanisms of PROTACs;

Identifying and validating novel targets and E3 ligases;

Employing the latest technology to overcome challenges and uncover the full therapeutic benefits of targeted protein degradation;

Emerging areas of protein degradation beyond oncology;

AUDIENCE

CTOs;

Chemical Biology & Therapeutics;

CMOs;

Solution Providers;

Principal Scientists;

R&D Pharm Leaders;

Research Advisors;

Drug Developers;

INDUSTRIES

Pharmaceutical;

Biotech infostructure;

Research and development centers;

Keynote Speakers
James Wilkinson

VP of Sales and Customer Success at Refeyn

Andrew Zhang

Associate Director at Astrazeneca

Bomie Han

Research Advisor at Eli Lilly and Company

Haojie Huang, PH.D.

Professor and Director of Basic Urologic Research at Mayo Clinic

Dr. Gabriela Chiosis

Member and Tri-Institutional Professor at Sloan Kettering Institute for Cancer Center

Hong-yu Li , Ph.D.

Professor at University of Arkansas for Medical Sciences

Wayne Hancock

Professor of Pathology and Laboratory Medicine at Perelman School of Medicine at the University of Pennsylvania

Dr. Wei Zhang

Assistant Professor at University of Guelph

Kristin Riching

Senior Scientist at Promega

Prof. Dr. Elmar Wolf

Universität Würzburg, Chair of Biochemistry and Molecular Biology

Xavier Jacq

VP Biology at Almac Discovery

Daniel Robbins

Associate Director at Nurix Therapeutics

Zhenyi Hu

Postdoctoral Associate  at Yale university

Tauseef Butt

President and CEO at Progenra

Zuzanna Kozicka

PhD candidate at Friedrich Miescher Institute for Biomedical Research

Media Partners